PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Gross profit growth of 4.31% while CRVO is zero. Bruce Berkowitz would see if minimal improvements could expand further.
8.25%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
8.25%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
12.55%
Net income growth under 50% of CRVO's 201.76%. Michael Burry would suspect the firm is falling well behind a key competitor.
15.52%
EPS growth under 50% of CRVO's 141.94%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
15.52%
Diluted EPS growth under 50% of CRVO's 54.84%. Michael Burry would worry about an eroding competitive position or excessive dilution.
3.21%
Share reduction more than 1.5x CRVO's 143.25%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.21%
Diluted share reduction more than 1.5x CRVO's 176.95%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.46%
OCF growth under 50% of CRVO's 202.14%. Michael Burry might suspect questionable revenue recognition or rising costs.
18.52%
FCF growth under 50% of CRVO's 202.14%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.04%
10Y OCF/share CAGR at 75-90% of CRVO's 100.09%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
77.11%
5Y OCF/share CAGR at 75-90% of CRVO's 101.92%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
-27.06%
Negative 3Y OCF/share CAGR while CRVO stands at 119.87%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
72.83%
Net income/share CAGR at 50-75% of CRVO's 100.02%. Martin Whitman might question if the firm’s product or cost base lags behind.
70.62%
5Y net income/share CAGR at 50-75% of CRVO's 100.43%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-36.68%
Negative 3Y CAGR while CRVO is 112.50%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.68%
10Y equity/share CAGR in line with CRVO's 100.02%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
-48.78%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-45.28%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while CRVO invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-20.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.39%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.88%
R&D dropping or stable vs. CRVO's 2381.80%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-40.17%
We cut SG&A while CRVO invests at 8.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.